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who initiated therapy during year 2002 with either an inhaled
corticosteroid or an anticholinergic (ﬁrst ﬁll date identiﬁed as
index date) were included in the analyses. Patients were followed
for one year prior to and one year after the index date. Rate of
switching and augmentation between the two groups was ana-
lyzed descriptively. Multivariate analyses controlling for patient
demographics, comorbidities, baseline health resource utilization
and physician specialty were used to compare costs between the
two groups. RESULTS: Of the 8392 patients identiﬁed as having
COPD, 467 (5.56%) initiated an inhaled corticosteroid and 495
(5.90%) initiated an anticholinergic. Rate of switching (12% 
vs. 10%) and augmentation (32% vs. 24%) was higher in the
inhaled corticosteroid group as compared to the anticholinergic
group. After adjusting for the confounding factors, multivariate
analysis revealed that the initiating inhaled corticosteroid group
had 68% higher respiratory costs and 20% higher overall costs
as compared to the initiating anticholinergic group during the
one-year follow-up period (p < 0.05). CONCLUSIONS: The
inhaled corticosteroid users had higher rates of switching/aug-
mentation and higher respiratory and overall costs as compared
to the anticholinergic users. Future research determining the
reasons for higher follow-up cost in the inhaled corticosteroid
group would be helpful.
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OBJECTIVES: The Canadian Thoracic Society (CTS) guidelines
for the management of Chronic Obstructive Pulmonary Disease
(COPD) recommend incorporating combination therapy [long-
acting B2-agonist (LABA) and an inhaled-corticosteroid (ICS)]
for select COPD patients but have not evaluated the associated
economic implications. Our objective was to provide economic
information to inform decision makers whether to recommend
combination therapy to none, all, or a select group of COPD
patients. METHODS: Using clinical guidelines and current man-
agement of COPD as the basis for the analysis, a markov model
was constructed to determine, from a health systems perspective,
the cost-effectiveness of combination therapy versus LABA alone
between four treatment strategies: 1) maintenance therapy for all
patients using LABA alone (base case); and in addition to the
base case, 2) provide combination therapy for severe cases
(forced expiratory volume in 1 second [FEV1] < 35% predicted);
3) provide combination therapy for moderate or severe cases
(FEV1 < 50% predicted); and 4) provide combination therapy
for all COPD patients. Estimates of mortality, exacerbation and
disease progression rates, and outcomes (QALY) were derived
from a systematic review of the literature. Cost estimates were
based on current Alberta healthcare costs. A time horizon of 3
years was used. RESULTS: Beginning with the lowest cost inter-
vention of LABA for all cases: the incremental cost-effectiveness
ratio (ICER) of providing combination therapy for severe
patients was $9670 per QALY gained. The marginal ICER for
providing combination therapy for moderate and severe cases 
is $31,606 per QALY gained and providing combination therapy
for all stages of disease was $271,241 per QALY gained. 
CONCLUSION: It would be cost-effective to provide combina-
tion therapy for moderate and severe COPD patients. This analy-
sis has signiﬁcant implications for the planned revision of CTS
guidelines because it promotes the wider use of combination
therapy in COPD populations with greater severity.
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OBJECTIVES: COPD is a leading cause of morbidity and mor-
tality in the U.S., and is a major source of healthcare costs. Life-
time costs of COPD and its impact on life expectancy have 
not been adequately quantiﬁed. METHODS: We developed a
Markov model to project mortality and costs from COPD over
an individual’s remaining lifetime. The model proﬁles patients
with diagnosed COPD by sex, age (30, 40, 50, 60, 70, 80 years),
smoking status (current, former, never smoker), and COPD
severity (GOLD stages I–IV). Changes/transitions for these
factors, along with mortality, occur in each one-year model cycle.
Data were obtained from published sources and analyses of gov-
ernment survey and claims databases. The model projects direct
costs (undiscounted and discounted to 2005 US$ at 3% per
annum) and life expectancy (age at death and quality-adjusted
life years [QALYs] remaining). RESULTS: For a “typical” COPD
patient (60 years old, former smoker, GOLD stage I or II), dis-
counted lifetime costs of COPD were projected to range from
$38,000–$74,000 (men) and $43,000–$85,000 (women) for
GOLD stages I and II, respectively. Unadjusted remaining life
expectancy was 19.6/22.0 years (men/women) for GOLD stage
I, and 16.6/19.0 years (men/women) for GOLD stage II.
Men/women in GOLD stages I and II respectively had 1.4/2.3
and 4.4/5.3 fewer years remaining in life compared to average
60-year-olds in the general U.S. population. Quality-adjusted life
expectancy for men/women was 17.0/18.9 and 12.0/13.7 QALYs
for GOLD stages I and II, respectively. CONCLUSION: Lifetime
burden of COPD for individuals with the disease is considerable.
Costs and life-years lost for GOLD stage II patients are about
double to triple for those in GOLD stage I. These results high-
light the potential clinical and economic beneﬁts of slowing
disease progression.
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Little is known about the costs of treating idiopathic pulmonary
ﬁbrosis (IFP), an infrequent but often fatal chronic respiratory
disease. OBJECTIVE: To assess resource use and costs of care
for IPF, pulmonary care, and all healthcare services among newly
diagnosed IPF patients. METHODS: Patients newly diagnosed
with IPF were identiﬁed from the administrative claims records
of a large state Medicaid program. Patients were selected for
inclusion if they had (1) 1+ inpatient claims or 2+ outpatient
claims listing a ICD-9-CM diagnosis of IPF (515, 516.3¥)
between July 1999-June 2003; and (2) fee-for-service, Medicaid-
only coverage for 12+ months before and after their ﬁrst
observed claim with an IPF diagnosis (“index date”). Patients
who died during the 12-month post-index period also were
included. Patients were excluded if they had an IPF diagnosis 
in the 12 months prior to the index date, or diagnoses for 
extrinsic allergic alveolitis, pneumoconioses, lung diseases due to
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external agents, lung involvement in non-pulmonary conditions,
or miscellaneous diseases of the lung/respiratory system. Study
measures were assessed over four time periods: 0–12 months pre-
and post-index, 13–24 months post-index, and 25+ months post-
index. Costs of IPF, pulmonary disease (ICD-9-CM 480–519),
and all healthcare services were estimated by category of
resource use. RESULTS: A total of 896 met all patient selection
criteria. They had a mean (SD) age of 48.1 (22.2) years, about
60% were female, and about 44% were white. Approximately
14% of patients died within 12 months of their index date Mean
monthly costs of IPF-related care varied from $148–$314
depending on the follow-up period. Mean monthly costs of all
patient care were more than $4000 higher among IPF versus
non-IPF patients in Florida Medicaid ($4360 vs. $315). CON-
CLUSIONS: Per-patient costs of IPF appear to be considerable
in this population.
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OBJECTIVES: The study evaluated the inﬂuence of tobacco
smoking on direct costs of treatment of chronic obstructive pul-
monary disease (COPD) exacerbations. METHODS: A total of
112 men who underwent treatment of COPD exacerbation in
the Military Institute of Health Service from November 2001 to
October 2002 were included in the study. The patients were qual-
iﬁed into one of three groups: I—never-smoking patients (n =
40), II—former smokers (n = 42); III—active smokers (n = 30).
RESULTS: The mean direct cost of exacerbation treatment was
USD 686.2 (SD 292.3) [group I—642.9 (SD 216.2); group II—
USD 595.4 (SD 193.2); group III—USD 871.1 (SD 401.9)]. No
signiﬁcant differences in treatment costs were found between the
group I and group II. The costs of inhospital treatment of COPD
were signiﬁcantly higher in the group III than in the groups I and
II. A linear correlation was found between each consecutive pack
year of addiction and the costs of exacerbation treatment in the
group III (R = 0.39, R2 = 0.13; p < 0.03). No similar relation-
ship was found in the former smokers’ group. CONCLUSION:
Active tobacco smoking by COPD patients is related to sig-
niﬁcantly higher direct costs of hospitalization due to COPD
exacerbations.
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OBJECTIVES: Assessment of the inﬂuence that a doctor taking
care of a patient has on direct costs of inhospital treatment of
chronic obstructive pulmonary disease (COPD) exacerbation.
METHODS: Medical documentation of patients who had under-
gone treatment of COPD exacerbation in the Military Institute
of Health Service from November 2001 to October 2002 was
studied retrospectively. Direct costs of hospitalization in 8 groups
of patients treated by different doctors (8 specialists, with a
similar length of experience), were compared. RESULTS: A total
of 182 patients were qualiﬁed into 8 study groups, each treated
by a different doctor. The mean hospitalization period was 7.6
(SD 3.1) days. The mean (discounted for 2005) cost of COPD
exacerbation treatment was USD 841.7 (SD 371.0). No statisti-
cally signiﬁcant differences between the groups were found in 
the mean age of the patients, strength of nicotine addiction
(expressed in pack years), severity of the disease and pulmonary
function indices. Differences between the mean direct costs of
treatment by individual doctors amounted to as much as 87%
[USD 690.6 (SD 401.5) vs. USD 1 291.8 (SD 438.6), p < 0.05],
and they resulted mainly from different length of hospitalization
and costs of additional examinations. CONCLUSION: A way of
taking care of a patient by a doctor signiﬁcantly inﬂuences direct
costs of inhospital treatment of COPD exacerbations.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) in infants at
high risk, such as premature babies, infants with bronchopul-
monary dysplasia (BPD), and children with congenital heart
disease (CHD) in an Austrian health care setting. METHODS:
A decision tree model was used to estimate the cost-effectiveness
of Palivizumab in high-risk children. The data sources included
published literature, the Palivizumab pivotal trials, ofﬁcial
price/tariff lists and national population statistics. The study was
conducted from the perspective of the health care purchaser
(HCP) (primary) and society (secondary). RESULTS: From the
perspective of the HCP, the incremental cost-effectiveness ratio
(ICER) for preterm infants is €4484/quality adjusted life year
(QALY) without discounting; and becomes €14,439/QALY dis-
counted. For children with BPD the ICER is €6719/QALY
without discounting and increases to €21,672/QALY after dis-
counting. In the CHD indication the ICER is €3115/QALY
undiscounted, while €11,390/QALY discounted. The results
from the society perspective were substantially more cost-effec-
tive in all study populations. In preterm children the ICER is
€1435/QALY without discounting, and becomes €4623/QALY
discounted. For children with BPD the ICER is €4881/QALY
undiscounted and €15,741/QALY after discounting. For the
CHD group the ICER is €251/QALY undiscounted, and
€917/QALY discounted. Sensitivity analyses conﬁrmed the
robustness of the model. CONCLUSION: This study showed
that Palivizumab is a cost-effective prevention against RSV infec-
tions in high-risk infants in Austria under the current health eco-
nomic standards.
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OBJECTIVES: Current treatment guidelines for COPD recom-
mend the use of bronchodilators for the management of patients
with mild to moderate disease and adding inhaled corticosteroids
for severe patients and patients with repeated exacerbations.
This analysis evaluates COPD patients initiating treatment 
with either an inhaled corticosteroid or an anticholinergic to
